H Pylori Guideline Revision Supplement 2022: Difference between revisions
From Guide to YKHC Medical Practices
mNo edit summary |
|||
| Line 23: | Line 23: | ||
==Guideline Changes== | ==Guideline Changes== | ||
#Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" (to prevent any confusion with Barrett's esophagus). | # Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" (to prevent any confusion with Barrett's esophagus). | ||
#Addition of box specifying test-of-cure details: | # Addition of box specifying test-of-cure details: | ||
:::* Either urea breath test (UBT), stool antigen test, or endoscopic biopsy (if indicated for other reasons; pathology or CLO-test). | |||
:::* No antibiotics or bismuth for FOUR weeks. | |||
:::* No PPI for TWO weeks. | |||
<br> | <br> | ||
<br> | <br> | ||
Revision as of 18:53, 15 January 2022
This guideline revision page addresses only the methods and results of the 2022 guideline update. For a broader review of the topic of H. pylori in Alaska Natives and for prior and/or ANMC guidelines, see the Helicobacter pylori in Alaska Natives page.
Reason[s] for update
Routine 2-year review/update.
Methods
- Review of latest ANMC H. pylori treatment guideline (Feb 19, 2020 , Archive)
- Updated literature search (PubMed, (alaska[Title] OR polar[Title] OR arctic[Title]) AND helicobacter[Title/Abstract]). This is a broader search than previously in that it looks for "helicobacter" in the abstract as well as the title.
- Attendance at the 2019 Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium
- >Hosted by the CDC in Anchorage, Alaska
- >Experts were longstanding, world-renown researchers
- >Results were published in Gastroenterology in April 2020[1]
Results
- ANMC H. Pylori Treatment Guideline has no significant changes pertinent to the YKHC guideline. Of note, ANMC has started a study of offering EGD for gastric cancer screening for patients with a first-degree relative (parent, sibling, or child) with gastric cancer; they are treating to eradicate H. pylori in this group regardless of findings; but this treatment is limited to the study patients and thus is not applicable to our practice in Bethel.
- PubMed search returned 49 articles, 12 of which were published since the last literature review. Only one of these articles addresses treatment in our setting, which is the CDC conference summary,[1] which continues to explicitly advocate the current algorithm/guideline (which was originally published by an international, circumpolar expert group in 2016[2])
Guideline Changes
- Under treatment indications, "Intestinal Metaplasia" is changed to "Gastric Intestinal Metaplasia" (to prevent any confusion with Barrett's esophagus).
- Addition of box specifying test-of-cure details:
- Either urea breath test (UBT), stool antigen test, or endoscopic biopsy (if indicated for other reasons; pathology or CLO-test).
- No antibiotics or bismuth for FOUR weeks.
- No PPI for TWO weeks.
Author: Andrew W. Swartz, MD
References
- ↑ 1.0 1.1 Nolen LD, Vindigni SM, Parsonnet J; Symposium leaders. Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium. Gastroenterology. 2020 Apr;158(5):1197-1201. doi: 10.1053/j.gastro.2019.11.299. PMID: 31836529; PMCID: PMC7103478. DOI:10.1053/j.gastro.2019.11.299
- ↑ McMahon BJ, Bruce MG, Koch A, et al. The diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert Commentary. Epidemiology and Infection. 2016;144(2):225-233. PMID:26094936. PMCID:PMC4697284. doi:10.1017/S0950268815001181.
